September 14, 2017 – 15:10-15:50: Pathogen specific trial design to target multidrug resistant bacteria (MDR )
Dr. Glenn E. Dale, Head of Early Development, Antimicrobials, will speak in the panel discussion about the big challenge – pathogen specific trial design to target multidrug resistant bacteria (MDR ).
- Screening hundreds of patients to enroll 1. How to overcome this while keeping trials ethical and producing robust statistical data?
- Getting patients to MDR clinical trial centers when they have life threatening infections
- Identifying the best comparator drug
- Using Bayesian statistical analysis and exploring the creation of clinical trial networks